| Pack Size | Single Vial, 10-Pack |
|---|
The Wolverine Stack pairs Ronin's two most-extensively-studied tissue-repair compounds — BPC-157 and TB-500 — at five milligrams of each in a single lyophilized vial, ten milligrams total. The format suits combined-peptide research at half the standalone-vial loading of each component, engaging two non-overlapping mechanism niches: VEGFR2-Akt-eNOS vascular signalling from BPC-157 and parent-Thymosin-β-4 actin-cytoskeleton dynamics from TB-500. Every Ronin batch is independently verified by Janoshik Analytical using HPLC for purity quantification of each component peptide and mass spectrometry for identity confirmation. Supplied as a lyophilized white-to-off-white powder in a sealed glass vial. For laboratory research use only — not for human or veterinary use.
Description
The Wolverine Stack is a fixed-ratio research formulation pairing two tissue-repair peptides in a single lyophilized vial. The vial holds five milligrams of BPC-157 plus five milligrams of TB-500, summing to ten milligrams of total peptide content. The two-compound pairing is sometimes referred to as the BPC-157 + TB-500 blend in research-supply documentation; "Wolverine Stack" is Ronin's catalog name for the same format.
One feature distinguishes this format from buying the two components separately: each vial holds half the peptide loading of a standalone single-compound vial. Ronin's BPC-157 standalone ships at 10 mg; this blend contributes 10 mg of BPC-157. Ronin's TB-500 standalone also ships at 10 mg; this blend contributes 10 mg of TB-500. Researchers choosing the blend get half the per-component peptide loading at convenient pre-mixed ratios, which suits cost-sensitive combined-peptide experiments or starter-format research before scaling up to standalone vials.
The compound is supplied as a sealed amber-glass vial under inert gas. Reconstitution with bacteriostatic water is required before either of the two component peptides can be drawn into an insulin syringe. Reconstitution math is per-component: a single 20 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL of BPC-157 and 5 mg/mL of TB-500 simultaneously — the two peptides share the same diluent volume at matched ten-milligram loadings.
The two component peptides occupy non-overlapping mechanism niches across the tissue-repair research literature. BPC-157 has been investigated for vascular and angiogenic signalling through VEGFR2 receptor activation and the downstream Akt-eNOS branch, alongside gastric-protection findings and growth-hormone-receptor upregulation in tendon fibroblasts (PMID 27847966, PMID 21030672). The 2021 Frontiers in Pharmacology review compiled the BPC-157 wound-healing literature across dermal, tendon, ligament, muscle, bone, peripheral-nerve, and vascular tissue categories (PMID 34267654). TB-500's parent Thymosin β-4 has been characterised across actin-cytoskeleton dynamics, cell migration, cardiac progenitor mobilisation, and corneal wound-healing in foundational and contemporary research (PMID 11579089, PMID 15565145, PMID 11950239).
The 2019 Cell and Tissue Research paper provided independent replication of BPC-157 musculoskeletal soft-tissue findings outside the originating Croatian laboratory (PMID 30915550). The 2024 Inflammopharmacology BPC-157 review (PMID 38980576) and the 2016 Vitamins and Hormones Thymosin β-4 dermal-healing review (PMID 27450738) compile contemporary research framings for each component peptide. Recent broader peptide-therapy reviews (PMID 41966639, PMID 41490200) cover both compounds in the wider research-context.
No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared either component peptide, or the blend formulation, as a drug for human or veterinary use. Neither compound is listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. Ronin Peptides ships the blend exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.
Mechanism in research literature
The blend's two components engage two molecular niches that do not overlap at the receptor or signalling-pathway level. Combined-peptide protocols often cite this non-overlap as the rationale for blend formats — each compound contributes activity at a distinct molecular target without competing for the same receptor or downstream effector.
BPC-157's mechanism centres on VEGFR2 receptor activation in vascular endothelial cells. A 2017 paper in the Journal of Molecular Medicine documented receptor activation and upregulation in vascular endothelium (PMID 27847966); the Akt-eNOS branch downstream of VEGFR2 has been characterised across multiple research groups, raising nitric-oxide output and supporting new vessel formation. A 2011 paper in the Journal of Applied Physiology documented growth-hormone-receptor expression upregulation in tendon fibroblasts following BPC-157 exposure, alongside enhanced cell migration and survival in tissue-repair models (PMID 21030672). The 2021 Frontiers in Pharmacology review compiled the wound-healing literature across multiple tissue categories (PMID 34267654).
TB-500's mechanism rests on the parent Thymosin β-4's role as the principal G-actin-sequestering peptide in mammalian cells. The seven-residue supply-form fragment retains the binding-active stretch of the parent. A 2001 Journal of Biological Chemistry paper characterised the ternary complex among profilin, Thymosin β-4, and actin (PMID 11579089). A 2004 Nature paper documented that the parent Thymosin β-4 activates integrin-linked kinase and supported cardiac cell migration, survival, and post-infarct repair in mouse models (PMID 15565145). A 1997 FASEB Journal paper described directional migration of human umbilical vein endothelial cells in response to the parent peptide, providing one of the foundational angiogenesis observations (PMID 9194528).
The two mechanism niches converge at the tissue-repair-and-cellular-response level — vascular signalling (BPC-157) and cytoskeletal dynamics (TB-500) collectively contribute to the broader tissue-repair research framings under which both compounds appear. The 2019 independent replication paper from a UK-based group examined BPC-157 musculoskeletal soft-tissue findings across an independent set of experimental conditions (PMID 30915550). The 2016 Thymosin β-4 dermal-healing review (PMID 27450738) provides the parallel TB-500-side compilation. Recent reviews (PMID 38980576, PMID 41966639, PMID 41490200) have placed both compounds into broader peptide-therapy framings.
Studied properties
Tissue-repair research forms the largest application bracket for combined-peptide research with the blend's two components. BPC-157's tendon-repair work, anchored by the 2011 Chang paper on tendon outgrowth, fibroblast migration, and post-injury survival (PMID 21030672), connects mechanistically to TB-500's cardiac and corneal repair findings (PMID 15565145, PMID 11950239). The cross-stream pattern of complementary tissue-repair findings has produced the rationale researchers cite for combined-peptide investigations.
Skin-and-dermal research forms a second cross-compound application bracket. BPC-157's wound-healing literature (PMID 34267654) and TB-500's parent dermal-healing literature (PMID 27450738) collectively cover dermal, tendon, ligament, muscle, bone, peripheral-nerve, and vascular tissue categories. The two-compound blend is sometimes preferred over a three- or four-component blend (such as Ronin's Glow Blend or KLOW Blend) when the research focus is specifically on the tissue-repair niche without the GHK-Cu skin-research or KPV anti-inflammatory components.
Independent replication of BPC-157 findings outside the originating Croatian laboratory has provided cross-laboratory credibility. The 2019 Cell and Tissue Research paper from a UK-based group examined the musculoskeletal soft-tissue literature and confirmed accelerated-healing observations across an independent set of experimental conditions (PMID 30915550). The 2024 Inflammopharmacology review compiled the most current animal-model results across the gastrointestinal-protection stream (PMID 38980576).
TB-500's research portfolio rests primarily on the parent Thymosin β-4 literature — the seven-residue supply-form fragment retains the binding-active stretch but has narrower direct-fragment characterisation. The 2001 ternary-complex JBC paper, the 2004 Nature cardiac-repair paper, the 2002 corneal alkali-injury paper, and the 1997 FASEB endothelial-migration paper collectively form the foundational stack (PMID 11579089, PMID 15565145, PMID 11950239, PMID 9194528).
Translation to human clinical application has been narrower than the breadth of the preclinical literature for either component. Recent reviews (PMID 41966639, PMID 41490200) compile contemporary framings; researchers consulting these reviews should attend to the regulatory context — neither compound is approved as a drug in any major jurisdiction.
Compound specifications
The blend contains two distinct compounds at the proportions listed below.
| Specification | BPC-157 | TB-500 |
|---|---|---|
| Content per vial | 10 mg | 10 mg |
| Sequence | GEPPPGKPADDAGLV | LKKTETQ |
| Length | 15 amino acids | 7 amino acids |
| Molecular formula | C62H98N16O22 | (7-residue acetate) |
| Molecular weight | 1419.55 g/mol | ~889 g/mol |
| CAS number | 137525-51-0 | (fragment) |
| PubChem CID | 9941957 | — |
| Mechanism niche | VEGFR2-Akt-eNOS pathway | Parent Thymosin β-4 G-actin sequestration |
Total peptide loading per vial: 10 mg. Form: lyophilized white-to-off-white powder. Solubility: bacteriostatic water; sterile water for injection. Storage: sealed amber-glass vial under inert gas. Purity: ≥99% per component by HPLC, verified per batch by Janoshik Analytical against the two expected molecular masses.
One specification note worth flagging: the COA returned for the blend reports the analytical results for each of the two component peptides separately. Investigators integrating the blend into mass-spec-coupled protocols should expect two distinct mass-spec peaks corresponding to the two components, plus characterisation of the salt and counterion forms returned in the per-batch documentation.
Storage and handling
Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.
Keep vials shielded from light, ideally in their original outer packaging. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.
After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window is four to six weeks at fridge temperature. Past that window, peptide concentration drifts downward through chemical degradation pathways. The 0.9% benzyl alcohol in bacteriostatic water holds back bacterial contamination but does not arrest hydrolysis, oxidation, and aggregation processes accumulating in any aqueous peptide solution. The two components may degrade at slightly different rates; the per-component COA mass-spec data is the only direct status confirmation.
When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.
The reconstituted product should be visually transparent and colourless with no suspended particulate. Discard any vial showing turbidity, suspended particulate, yellowing, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.
Compare with related blends and individual compounds
| Format | Components | Total peptide | Format at Ronin |
|---|---|---|---|
| Wolverine Stack | BPC-157 + TB-500 | 10 mg total (5 + 5) | 10 mg blend vial |
| Glow Blend | GHK-Cu + BPC-157 + TB-500 | 70 mg total (50 + 10 + 10) | 70 mg blend vial |
| KLOW Blend | GHK-Cu + BPC-157 + TB-500 + KPV | 80 mg total (50 + 10 + 10 + 10) | 80 mg blend vial |
| BPC-157 standalone | BPC-157 only | 20 mg per vial | 10 mg vial |
| TB-500 standalone | TB-500 only | 20 mg per vial | 10 mg vial |
The Wolverine Stack is the smallest of Ronin's three blend formats by total peptide content. Glow Blend adds GHK-Cu (50 mg loading); KLOW Blend further adds KPV. Investigators focused exclusively on the BPC-157 + TB-500 tissue-repair pairing — the most-studied combined research framing — use the Wolverine Stack format. Investigators wanting the dermal-research GHK-Cu component alongside the tissue-repair pair use Glow Blend; researchers wanting the additional anti-inflammatory KPV component use KLOW Blend. Each component peptide is also available as a standalone single-compound vial at 10 mg.
Reconstitution and laboratory handling
Reconstituting the Wolverine Stack follows the same procedure as a single-compound vial, with one important difference: the resulting solution contains two peptides at matched concentrations. A single 10 mg vial reconstituted with 2 mL of bacteriostatic water yields the following per-component working concentrations:
- BPC-157: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
- TB-500: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
Other diluent volumes scale linearly. A 1 mL reconstitution gives both components at 10 mg/mL. A 5 mL reconstitution gives both at 2 mg/mL. The matched ten-milligram loadings give the blend a one-to-one ratio between BPC-157 and TB-500 across all reconstitution volumes — a convenience for combined-peptide experiments where identical per-component working concentrations simplify downstream pipetting.
Reconstitution procedure:
- Bring both vials — peptide blend and bacteriostatic water — to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
- Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
- Refrigerate at 2–8 °C the moment reconstitution completes.
A finished preparation should be visually transparent and colourless with no suspended particulate. If the solution is hazy or contains visible material, treat it as degraded or contaminated and discard.
For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator handles per-component concentration arithmetic for blend formats.
Per-component dose ranges in published preclinical research differ across the two peptides. BPC-157 has been administered at 6 to 50 micrograms per kilogram in animal models across multiple routes. TB-500's parent Thymosin β-4 has been administered at micrograms-per-kilogram parenteral dosing in cardiac and corneal model systems. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.
Frequently asked questions
What is the Wolverine Stack?
The Wolverine Stack is Ronin's two-component research blend pairing BPC-157 (10 mg) with TB-500 (10 mg) in a single lyophilized vial — 20 milligrams of peptide total. Each component peptide is also available standalone from Ronin Peptides at 20 mg per vial. The blend format pairs the two peptides at convenient working concentrations for combined-peptide benchwork. The two components engage two non-overlapping mechanism niches across the tissue-repair research literature. Ronin supplies the blend as a lyophilized vial reconstituted with bacteriostatic water at the bench. Sale is limited to laboratory research applications; human and veterinary use are excluded.
Why is it called the Wolverine Stack?
"Wolverine Stack" is Ronin's catalog name for the BPC-157 + TB-500 blend format. The descriptive product name "BPC-157 + TB-500 Blend" appears as the alternate identifier and matches the URL slug used across the Ronin catalog. Both names refer to the same product: a two-component blend at five milligrams of each compound in a single lyophilized vial.
Why a blend rather than individual compounds?
Researchers studying combined-peptide protocols often examine BPC-157 and TB-500 together because the two peptides engage distinct molecular pathways that do not compete at the receptor or signalling-pathway level. The blend format provides convenient working concentrations at a fixed one-to-one ratio for combined-peptide benchwork, removing the need to reconstitute two separate vials and combine them at the bench. Researchers preferring independent concentration control can use the standalone single-compound vials for each component instead.
How is the 20 mg Wolverine Stack loaded?
The 20 mg Wolverine Stack contains ten milligrams each of BPC-157 and TB-500 in one lyophilized vial, matching the standalone single-vial loading of each component. It suits researchers running BPC-157 and TB-500 in parallel from a single reconstitution. A single reconstitution yields both peptides together at a one-to-one ratio. The matched ten-milligram loadings give the blend a one-to-one ratio between BPC-157 and TB-500 across all reconstitution volumes, simplifying combined-peptide bench arithmetic.
What is the regulatory status of the Wolverine Stack?
No regulatory body — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has approved either component peptide, or the blend formulation, as a drug for human or veterinary use. Neither compound is listed as a scheduled controlled substance under the international drug-control conventions or under the major national scheduling systems. The blend sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics.
Ronin Peptides supplies the blend as a research-grade reagent for laboratory and bench-research applications. Buyers operate under their own jurisdictional laws and any applicable institutional review protocols when handling the compound — Ronin Peptides assumes no oversight of downstream lab practice.
How is the Wolverine Stack verified?
Each batch passes through Janoshik Analytical — an independent peptide-analytics lab — for HPLC purity quantification of each of the two component peptides and MS identity confirmation of each component, with the minimum acceptance threshold set at 99 percent purity per component by HPLC. Every Janoshik COA includes a verification key that resolves at janoshik.com, plus per-component analytical results showing the two distinct compounds. To pull the COA covering the batch on your order, email support@roninpeptides.ca from the address used at checkout, with your order number; the typical reply turnaround is well under 24 hours.
How is the Wolverine Stack reconstituted?
The standard preparation is 2 mL of bacteriostatic water added to a 10 mg vial, producing a solution with BPC-157 at 2.5 mg/mL and TB-500 at 2.5 mg/mL. Inject the water against the inside wall of the vial — never directly onto the lyophilized powder, which causes foaming and surface denaturation. Swirl gently or invert slowly until fully dissolved (typically 30–60 seconds). Refrigerate at 2–8 °C immediately after reconstitution. Use the Ronin reconstitution calculator for non-standard volumes.
How do I receive the COA for my batch?
Email support@roninpeptides.ca from the email address used at checkout, with your order number (e.g., RP-CA-1234) and the compound name. We reply within 24 hours — typically the same business day — with the COA PDF attached. The COA includes the Janoshik verification key and per-component analytical results for the two blend components, which you can check independently at janoshik.com to confirm the test results match what the laboratory ran on your specific batch. COAs are not published publicly to protect supply-chain privacy and prevent competitor scraping.
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017;95(3):323-333. PMID: 27847966 | doi:10.1007/s00109-016-1488-y
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672 | doi:10.1152/japplphysiol.00945.2010
- Seiwerth S et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. PMID: 34267654 | doi:10.3389/fphar.2021.627533
- Gwyer D et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. PMID: 30915550 | doi:10.1007/s00441-019-03016-8
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024;32(5):3119-3161. PMID: 38980576 | doi:10.1007/s10787-024-01499-8
- Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem. 2001;276(49):45555-45563. PMID: 11579089 | doi:10.1074/jbc.M105723200
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145 | doi:10.1038/nature03000
- Malinda KM et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID: 9194528 | doi:10.1096/fasebj.11.6.9194528
- Sosne G et al. Thymosin beta 4 promotes corneal wound healing. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239 | doi:10.1006/exer.2001.1125
- Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. PMID: 27450738 | doi:10.1016/bs.vh.2016.04.005
- Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Med. 2026. PMID: 41966639 | doi:10.1007/s40279-026-02437-0
- Rahman OF et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 | doi:10.5435/JAAOSGlobal-D-25-00236
